Dulaglutide: Difference between revisions

<languages />

<translate>

{{Drug List/ja|state6=uncollapsed}}

{{Pathnav|Medication|Diabetes medication|GLP-1 receptor agonist|frame=1}}

| caption            =

<!-- Clinical data -->

| pronounce          =  

| ATC_supplemental  =

<!-- Legal status -->

| legal_AU          = S4

| legal_status      = <!--For countries not listed above-->

<!-- Pharmacokinetic data -->

| bioavailability    =  

| excretion          =

<!-- Identifiers -->

| CAS_number_Ref    =  

| synonyms          =

<!-- Chemical and physical data -->

| IUPAC_name        =  

}}

<!-- Definition and medical sues -->

'''Dulaglutide''', sold under the brand name '''Trulicity''' among others, is a [[medication]] used for the treatment of [[type 2 diabetes]] in combination with diet and exercise. It is also approved in the United States for the reduction of [[major adverse cardiovascular events]] in adults with type 2 diabetes who have established [[cardiovascular disease]] or multiple cardiovascular risk factors. It is a once-weekly injection.

The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.

<!-- History and culture -->

It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. [[glucagon-like peptide-1|GLP-1]] is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The [[Food and Drug Administration]] (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2021, it was the 70th most commonly prescribed medication in the United States, with more than 9{{nbsp}}million prescriptions.

The compound is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular [[metformin]], [[sulfonylurea]]s, [[thiazolidinedione]]s, and [[insulin]] taken concomitantly with meals.

The medication's phase 3 clinical trial program demonstrated reductions in hemoglobin A1c of approximately 1% with the 0.75&nbsp;mg and 1.5&nbsp;mg doses of the medication, along with approximately 5 pounds of weight loss on average. The higher 3.0&nbsp;mg and 4.5&nbsp;mg doses that were approved in 2020 demonstrated hemoglobin A1c reductions closer to 1.5% and slightly more weight loss.

A 2017 [[meta-analysis]] did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics.

The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]]. Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylurea]]s or [[insulin]]. There is also a potential risk of [[medullary thyroid carcinoma]] associated with the use of the drug.

The compound is contraindicated in subjects with [[hypersensitivity]] to the [[active ingredient]] or any of the product's components.

People with a personal or family history of [[medullary thyroid cancer]] (MTC) or affected by [[multiple endocrine neoplasia]] type 2 should not take dulaglutide, because it could increase the risk of these cancers.

Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increases insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by [[L cell]]s of the gastrointestinal mucosa in response to a meal.

The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control).

The U.S. [[Food and Drug Administration]] (FDA) approved dulaglutide with a [[Risk Evaluation and Mitigation Strategies|Risk Evaluation and Mitigation Strategy]] (REMS), and granted the approval of Trulicity to [[Eli Lilly and Company]]. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of [[medullary thyroid carcinoma]]  associated with the drug.

In 2020, the FDA approved two higher doses of the medication, 3.0&nbsp;mg and 4.5&nbsp;mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.

* {{cite journal | vauthors = Scott LJ | title = Dulaglutide: A Review in Type 2 Diabetes | journal = Drugs | volume = 80 | issue = 2 | pages = 197–208 | date = February 2020 | pmid = 32002850 | doi = 10.1007/s40265-020-01260-9 | s2cid = 210954338 }}

* {{cite journal | vauthors = Edwards KL, Minze MG | title = Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | journal = Core Evidence | volume = 10 | pages = 11–21 | date = 2015 | pmid = 25657615 | pmc = 4295897 | doi = 10.2147/CE.S55944 | doi-access = free }}

* {{cite journal | vauthors = Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J | title = A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | journal = Diabetes Therapy | volume = 10 | issue = 1 | pages = 5–19 | date = February 2019 | pmid = 30506340 | pmc = 6349277 | doi = 10.1007/s13300-018-0535-9 }}

{{Oral hypoglycemics and insulin analogs|state=expanded}}

{{Portal bar | Medicine}}

{{二次利用|date=7 February 2024}}

[[Category:Drugs developed by Eli Lilly and Company]]